This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Leucine-rich repeats and death domain containing (LRDD; PIDD) as a biomarker for resistance to platinum chemotherapy in non-small cell lung cancer (NSCLC)	<p>Studies in mice and in cell culture suggest that PIDD upregulation could be a biomarker of NSCLC resistance to platinum chemotherapy. In multiple mouse models of NSCLC, prolonged cisplatin treatment led to platinum-resistant tumors that had greater DNA repair capacity than cisplatin-naïve tumors. In three human NSCLC cell lines, cisplatin led to greater PIDD expression than buffer control. In those cell lines, overexpression of PIDD correlated with increased cisplatin resistance. Next steps could include evaluating the effects of other platinum drugs on PIDD expression in mouse cancer models.</p> <p>SciBX 3(17); doi:10.1038/scibx.2010.541 Published online April 29, 2010</p>	Patent and licensing status unavailable	<p>Oliver, T.G. <i>et al. Genes Dev.</i>; published online April 14, 2010; doi:10.1101/gad.1897010</p> <p>Contact: Tyler Jacks, Massachusetts Institute of Technology, Cambridge, Mass. e-mail: tjacks@mit.edu</p>